The global blood preparation market size was valued at USD 36.7 billion in 2018and is projected to expand at a CAGR of 5.6% from 2019 to 2026. Growing demand for blood and its components in surgical procedures is expected to be a key factor driving the market. According to the Healthcare Cost and Utilization Project (HCUP) Statistical Briefs, blood transfusion was the most common procedure performed during hospitalizations for the period from 2006 to 2015 in the U.S.
Some biopharmaceutical companies are financing resources for the development of new drugs. Organizations, such as the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), are taking initiatives for raising awareness levels via programs that aim to prevent thrombosis-associated complications in early stages. Besides, a growing geriatric population base and rising healthcare expenditures are likely to boost the market further.
The introduction of novel technologies along with the increasing usage of plasma in the pharmaceutical industry is further projected to contribute to market growth over the forecast period. Various governments across the globe are focusing on increasing the number of blood donations by applying reimbursement policies, such as monetary incentives for donors. This factor is also expected to help augment the growth of the global market over the next few years.
Based on regional markets, North America is projected to be the largest market while APAC is expected to register the fastest growth during the forecast years. The growth of the APAC region can be attributed to the presence of sophisticated healthcare infrastructure, especially in Japan and Australia. Moreover, favorable government initiatives and several untapped opportunities in the emerging markets of China and India will drive the regional market further.
Based on the product, the blood preparation market is segmented into whole blood, derivatives, and components. The whole blood product segment held the largest market share in 2018. Increasing demand for whole blood for major surgeries and transfusions along with its advantages, such as easy availability, low cost, and maintenance, is the major factor contributing to the segment’s high share.
On the other hand, blood derivatives are likely to be the fastest-growing segment over the forecast years. The presence of government initiatives for the development of plasma-derived proteins, such as immunoglobulins, coagulation factor products, human fibrin foam, dried human plasma, and human thrombin, are expected to drive market growth.
Blood derivatives, such as intravenous immunoglobulin and hyperimmune, are used to boost immunity in cases of life-threatening infections, such as Ebola. Increasing the prevalence of such diseases, the introduction of advanced technologies to separate the components, and the launch of blood-derived medicines are the factors anticipated to boost the segment growth.
The antithrombotic and anticoagulants market is categorized based on type into platelet aggregation inhibitors, fibrinolytic, and anticoagulants. Among these, anticoagulants led the type segment in 2018 and are expected to register a lucrative CAGR from 2019 to 2026. This growth is attributed to the introduction of new products with higher efficacy and the potential commercialization of new products currently in the pipeline.
Biopharmaceutical companies are upgrading their products by launching novel and more efficient anticoagulant drugs in the market. Re-launch of some key drug products, such as Urokinase in North America, is expected to fuel its growth in the coming years. Anticoagulant drugs include heparins, vitamin K antagonists, direct thrombin inhibitors, and direct factor Xa inhibitors.
Based on the application, the market has been segmented into thrombocytosis, pulmonary embolism, renal impairment, angina blood vessel complications, and others. Among these, antithrombotic products are widely used in thrombocytosis. Higher platelet count leads to coagulation of blood in the circulatory system, which ultimately causes life-threatening heart conditions. Thrombocytosis is classified as primary and secondary. Primary thrombocytosis is uncommon affecting around 24 individuals per million globally. It is prevalent in middle-aged people and women below 40 years. Secondary thrombocytosis is more common due to the conditions, such as hyposplenism, splenectomy, asplenia, hemorrhage, osteosarcoma, and rheumatoid arthritis.
Angina blood vessel complications are expected to grow at the fastest CAGR during the forecast period owing to rising R&D for the development of anticoagulants for cardiac problems and increasing prevalence of Cardiovascular Disorders (CVDs). Angina pectoris is characterized by severe pain in the chest and discomfort owing to insufficient oxygen supply to the heart. Although the main treatment for angina is nitroglycerine, the use of anticoagulants is significant owing to the frequency of complications in the former. Furthermore, a rise in lifestyle-associated diseases, the popularity of oral anticoagulants, growing patient awareness, increased healthcare expenditure, and favorable government policies are the factors driving the segment.
North America led the overall market in terms of revenue in 2018 owing to the high incidence of CVDs, leukemia, and hematological and neurological diseases in the region. Higher patient awareness and healthcare expenditure levels along with the presence of sophisticated healthcare infrastructure will boost the region’s growth further. The Asia Pacific is expected to witness the fastest growth on account of improving healthcare infrastructure, the presence of untapped opportunities, economic development, and rising initiatives by private and public organizations.
Key companies in the market are AstraZeneca PLC; Sanofi S.A.; LEO Pharma A/S; Bristol-Myers Squibb Company; Baxter International, Inc.; Pfizer, Inc.; Portola Pharmaceuticals, Inc.; and GlaxoSmithKline PLC. Most of the companies have adopted strategies, such as new product launches, mergers and acquisitions, and collaborations, to increase their market share. For instance, in June 2017, Portola Pharmaceuticals, Inc. received FDA approval for the commercial launch of Bevyxxa, a novel oral anticoagulant drug.
The base year for estimation
Actual estimates/Historical data
2014 - 2017
2019 - 2026
Revenue in USD Million and CAGR from 2019 to 2026
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
U.S., Canada, U.K., Germany, Spain, France, Italy, Russia, China, Japan, India, South Korea, Singapore, Australia, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, and UAE
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5-analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2026. For this study, Grand View Research has segmented the global blood preparation market report based on the product, type, application, and region:
Product Outlook (Revenue, USD Million, 2014 - 2026)
Whole Blood Components
Packed Red Cells
Leukocyte Reduced Red Blood Cells
Antithrombotic and Anticoagulants Type Outlook (Revenue, USD Million, 2014 - 2026)
Platelet Aggregation Inhibitors
Tissue Plasminogen Activator (tPA)
Low Molecular Weight Heparin (LMWH)
Ultra-low Molecular Weight Heparin
Vitamin K Antagonists
Direct Thrombin Inhibitors
Direct Factor Xa Inhibitors
Antithrombotic and Anticoagulants Application Outlook (Revenue, USD Million, 2014 - 2026)
Angina Blood Vessel Complications
Regional Outlook (Revenue, USD Million, 2014 - 2026)
Middle East & Africa
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.